Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Seeking Alpha / 2 hours from now 1 Views
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator
Comments